Glycomimetics Inc. buy tamam
Start price
17.10.17
/
50%
€10.18
Target price
12.12.17
€16.24
Performance (%)
57.88%
End price
12.12.17
€16.08
Summary
This prediction ended on 12.12.17 with a price of €16.08. The BUY prediction by tamam for Glycomimetics Inc. saw massive gains of 57.88%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Glycomimetics Inc. | 7.708% | 7.708% | -84.966% | -88.041% |
| iShares Core DAX® | -1.042% | 2.220% | 14.279% | 15.463% |
| iShares Nasdaq 100 | -1.361% | 3.207% | 26.657% | 53.266% |
| iShares Nikkei 225® | -0.044% | -1.680% | 5.941% | 4.271% |
| iShares S&P 500 | -0.480% | 2.165% | 23.067% | 45.283% |
Comments by tamam for this prediction
In the thread Glycomimetics Inc. diskutieren
GlycoMimetics Is An Exceptional Investment Opportunity
GMI-1271 shows impressive efficacy and safety profile (as of interim Phase 2).
Recent mixed shelf offering hints at major near-term upside potentials.
Longer term, GLYC seems to have found an important biomarker (E-selectin) that may expand TAM exponentially.
FDA Breakthrough Designation will expedite the development process.
Smart institutional investors are behind GLYC as significant long-term investors.
For the longer term, GLYC seems to have found an important biomarker that will allow it to expand into multiple tumor types (key opportunity is multiple myeloma - second largest blood cancer market) - significantly expanding its TAM. This will attract many players in oncology to partner/acquire GLYC once the company proves to be important in AML. In fact, GLYC is already running a Phase 1 trial inmultiple myeloma with GMI-1271 and management has started talking about this opportunity.The comment has been deleted